Tricida, Inc. is a pharmaceutical company that's working towards the development and commercialization of its drug candidate, veverimer (TRC101), for the treatment of metabolic acidosis in patients with CKD. Veverimer is a polymer that's orally-administered and non-absorbed by the body. The company is currently undertaking the VALOR-CKD clinical trial to assess the drug's effectiveness and safety in delaying CKD progression in patients with metabolic acidosis. Chronic metabolic acidosis currently has no FDA-approved treatments.